Comparative Pharmacology
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus SULSOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus SULSOXIN.
SULFONAMIDES DUPLEX vs SULSOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
None Documented
None Documented
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic